Cargando…

Positive effects of Lianhuaqingwen granules in COVID-19 patients: A retrospective study of 248 cases

ETHNOPHARMACOLOGICAL RELEVANCE: Lianhuaqingwen (LHQW) is a Chinese medicine, developed from appropriate addition and reduction of combined traditional Chinese medicine (TCM) Yinqiao San and Maxing Shigan decoction. LHQW has been used in routine influenza treatment for decades and plays a role in a b...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Pan, Li, Jing, Tu, Shenghao, Wu, Yanran, Peng, Yongtiao, Chen, Gang, Chen, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139441/
https://www.ncbi.nlm.nih.gov/pubmed/34029640
http://dx.doi.org/10.1016/j.jep.2021.114220
_version_ 1783696008059813888
author Shen, Pan
Li, Jing
Tu, Shenghao
Wu, Yanran
Peng, Yongtiao
Chen, Gang
Chen, Chao
author_facet Shen, Pan
Li, Jing
Tu, Shenghao
Wu, Yanran
Peng, Yongtiao
Chen, Gang
Chen, Chao
author_sort Shen, Pan
collection PubMed
description ETHNOPHARMACOLOGICAL RELEVANCE: Lianhuaqingwen (LHQW) is a Chinese medicine, developed from appropriate addition and reduction of combined traditional Chinese medicine (TCM) Yinqiao San and Maxing Shigan decoction. LHQW has been used in routine influenza treatment for decades and plays a role in a broad-spectrum therapy on various influenza viruses. Aims of the study: The therapeutic effects of LHQW in coronavirus disease 2019 (COVID-19) have not been fully elucidated. A retrospective study was conducted in patients with COVID-19 to evaluate the influence of LHQW on laboratory results related to the disease, and to provide evidence for the clinical practice of TCM. MATERIALS AND METHODS: We retrospectively collected 248 patients who met the moderate type COVID-19 diagnostic criteria, and received treatment in Tongji Hospital. Patients were divided into control (158 cases, standard treatment) and LHQW treatment (90 cases, standard treatment combined with LHQW) groups according to the different treatments administered. All laboratory data were obtained after 5–7 days’ treatment. RESULTS: In this study, the average patient age was 58.95 years and 131 patients were male. The two groups were comparable in demographic characteristics, symptoms, and treatment. Compared with in the control group, D-dimer and erythrocyte sedimentation rate were significantly lower in the LHQW treatment group (2.47 ± 4.67 vs. 1.68 ± 3.61; 44.47 ± 30.24 vs. 35.39 ± 27.43; both P < 0.05). Lymphocyte counts, albumin and hemoglobin levels were higher in the LHQW treatment group than those in the control group (1.00 ± 0.46 vs. 1.13 ± 0.5; 34.39 ± 5.2 vs. 35.71 ± 4.76; 127.03 ± 16.58 vs. 131.11 ± 14.66; both P < 0.05). CONCLUSION: The study showed that LHQW significantly improved laboratory results of patients with COVID-19 and could be effectively applied alongside standard treatment of patients with moderate type COVID-19, providing preliminary clinical research evidence for the use of TCM in treatment of this disease.
format Online
Article
Text
id pubmed-8139441
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-81394412021-05-24 Positive effects of Lianhuaqingwen granules in COVID-19 patients: A retrospective study of 248 cases Shen, Pan Li, Jing Tu, Shenghao Wu, Yanran Peng, Yongtiao Chen, Gang Chen, Chao J Ethnopharmacol Article ETHNOPHARMACOLOGICAL RELEVANCE: Lianhuaqingwen (LHQW) is a Chinese medicine, developed from appropriate addition and reduction of combined traditional Chinese medicine (TCM) Yinqiao San and Maxing Shigan decoction. LHQW has been used in routine influenza treatment for decades and plays a role in a broad-spectrum therapy on various influenza viruses. Aims of the study: The therapeutic effects of LHQW in coronavirus disease 2019 (COVID-19) have not been fully elucidated. A retrospective study was conducted in patients with COVID-19 to evaluate the influence of LHQW on laboratory results related to the disease, and to provide evidence for the clinical practice of TCM. MATERIALS AND METHODS: We retrospectively collected 248 patients who met the moderate type COVID-19 diagnostic criteria, and received treatment in Tongji Hospital. Patients were divided into control (158 cases, standard treatment) and LHQW treatment (90 cases, standard treatment combined with LHQW) groups according to the different treatments administered. All laboratory data were obtained after 5–7 days’ treatment. RESULTS: In this study, the average patient age was 58.95 years and 131 patients were male. The two groups were comparable in demographic characteristics, symptoms, and treatment. Compared with in the control group, D-dimer and erythrocyte sedimentation rate were significantly lower in the LHQW treatment group (2.47 ± 4.67 vs. 1.68 ± 3.61; 44.47 ± 30.24 vs. 35.39 ± 27.43; both P < 0.05). Lymphocyte counts, albumin and hemoglobin levels were higher in the LHQW treatment group than those in the control group (1.00 ± 0.46 vs. 1.13 ± 0.5; 34.39 ± 5.2 vs. 35.71 ± 4.76; 127.03 ± 16.58 vs. 131.11 ± 14.66; both P < 0.05). CONCLUSION: The study showed that LHQW significantly improved laboratory results of patients with COVID-19 and could be effectively applied alongside standard treatment of patients with moderate type COVID-19, providing preliminary clinical research evidence for the use of TCM in treatment of this disease. Elsevier B.V. 2021-10-05 2021-05-21 /pmc/articles/PMC8139441/ /pubmed/34029640 http://dx.doi.org/10.1016/j.jep.2021.114220 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Shen, Pan
Li, Jing
Tu, Shenghao
Wu, Yanran
Peng, Yongtiao
Chen, Gang
Chen, Chao
Positive effects of Lianhuaqingwen granules in COVID-19 patients: A retrospective study of 248 cases
title Positive effects of Lianhuaqingwen granules in COVID-19 patients: A retrospective study of 248 cases
title_full Positive effects of Lianhuaqingwen granules in COVID-19 patients: A retrospective study of 248 cases
title_fullStr Positive effects of Lianhuaqingwen granules in COVID-19 patients: A retrospective study of 248 cases
title_full_unstemmed Positive effects of Lianhuaqingwen granules in COVID-19 patients: A retrospective study of 248 cases
title_short Positive effects of Lianhuaqingwen granules in COVID-19 patients: A retrospective study of 248 cases
title_sort positive effects of lianhuaqingwen granules in covid-19 patients: a retrospective study of 248 cases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139441/
https://www.ncbi.nlm.nih.gov/pubmed/34029640
http://dx.doi.org/10.1016/j.jep.2021.114220
work_keys_str_mv AT shenpan positiveeffectsoflianhuaqingwengranulesincovid19patientsaretrospectivestudyof248cases
AT lijing positiveeffectsoflianhuaqingwengranulesincovid19patientsaretrospectivestudyof248cases
AT tushenghao positiveeffectsoflianhuaqingwengranulesincovid19patientsaretrospectivestudyof248cases
AT wuyanran positiveeffectsoflianhuaqingwengranulesincovid19patientsaretrospectivestudyof248cases
AT pengyongtiao positiveeffectsoflianhuaqingwengranulesincovid19patientsaretrospectivestudyof248cases
AT chengang positiveeffectsoflianhuaqingwengranulesincovid19patientsaretrospectivestudyof248cases
AT chenchao positiveeffectsoflianhuaqingwengranulesincovid19patientsaretrospectivestudyof248cases